Leukemia & lymphomaHumansCapillary Leak SyndromeDendritic CellsHematologic NeoplasmsRecombinant Fusion Proteins
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Andrew A Lane, Cristina Papayannidis, Emanuele Angelucci, James McCloskey, Gary J Schiller, Adolfo de la Fuente Burguera, Pau Montesinos, Yasir Nagarwala, Marco Herling, Gabriel Mannis, Naveen Pemmaraju
Published: 202510.1080/10428194.2025.2557505
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, orphan hematologic malignancy characterized by cells expressing CD123 and other markers. The only drug approved for BPDCN is tagraxofusp, a first-in-class CD123-targeted therapy.…
Preview only. Read the full abstract at the source